Skip to main content
Conference Coverage

Use of a 12-Gene DCIS Score to Guide Radiotherapy Decisions for Patients With Ductal Carcinoma in Situ

Featuring Seema Khan, MD

 

Seema Khan, MD, Northwestern University School of Medicine, Chicago, Illinois, discussed 5-year clinical outcomes from E4112 which identified that >90% of patients who underwent a 12-gene DCIS score to predict radiotherapy benefit followed DS-based recommendations.

These results were first presented at the 2023 San Antonio Breast Cancer Symposium.


Source:

Khan S, Romanoff J, Gastonis C, et al. Magnetic resonance imaging and a 12-gene expression assay to optimize local therapy for ductal carcinoma in situ: 5-year clinical outcomes of E4112. Presented at the 2023 San Antonio Breast Cancer Symposium; December 5-9; San Antonio, Texas. Abstract GS03-01

© 2023 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.